Logo image of ANIP

ANI PHARMACEUTICALS INC (ANIP) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:ANIP - US00182C1036 - Common Stock

82.99 USD
-2.4 (-2.81%)
Last: 1/23/2026, 8:00:00 PM
82.99 USD
0 (0%)
After Hours: 1/23/2026, 8:00:00 PM

ANIP Key Statistics, Chart & Performance

Key Statistics
Market Cap1.86B
Revenue(TTM)826.88M
Net Income(TTM)34.14M
Shares22.47M
Float19.14M
52 Week High99.5
52 Week Low54.1
Yearly Dividend0.08
Dividend Yield0%
EPS(TTM)7.17
PE11.57
Fwd PE9.54
Earnings (Next)02-26
IPO2000-05-04
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
ANIP short term performance overview.The bars show the price performance of ANIP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20

ANIP long term performance overview.The bars show the price performance of ANIP in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80

The current stock price of ANIP is 82.99 USD. In the past month the price increased by 2.8%. In the past year, price increased by 41.52%.

ANI PHARMACEUTICALS INC / ANIP Daily stock chart

ANIP Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to ANIP. When comparing the yearly performance of all stocks, ANIP is one of the better performing stocks in the market, outperforming 77.14% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ANIP Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to ANIP. Both the profitability and the financial health of ANIP get a neutral evaluation. Nothing too spectacular is happening here.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ANIP Financial Highlights

Over the last trailing twelve months ANIP reported a non-GAAP Earnings per Share(EPS) of 7.17. The EPS increased by 56.89% compared to the year before.


Industry RankSector Rank
PM (TTM) 4.13%
ROA 2.42%
ROE 6.75%
Debt/Equity 1.2
Chartmill High Growth Momentum
EPS Q2Q%52.24%
Sales Q2Q%53.58%
EPS 1Y (TTM)56.89%
Revenue 1Y (TTM)19.34%

ANIP Forecast & Estimates

14 analysts have analysed ANIP and the average price target is 110.6 USD. This implies a price increase of 33.27% is expected in the next year compared to the current price of 82.99.

For the next year, analysts expect an EPS growth of 48.17% and a revenue growth 45.11% for ANIP


Analysts
Analysts84.29
Price Target110.6 (33.27%)
EPS Next Y48.17%
Revenue Next Year45.11%

ANIP Ownership

Ownership
Inst Owners93.39%
Ins Owners6.87%
Short Float %15.48%
Short Ratio6.19

About ANIP

Company Profile

ANIP logo image ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 897 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

Company Info

ANI PHARMACEUTICALS INC

210 Main Street West

Baudette MINNESOTA 56623 US

CEO: Nikhil Lalwani

Employees: 897

ANIP Company Website

ANIP Investor Relations

Phone: 12186343500

ANI PHARMACEUTICALS INC / ANIP FAQ

What does ANIP do?

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 897 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.


Can you provide the latest stock price for ANI PHARMACEUTICALS INC?

The current stock price of ANIP is 82.99 USD. The price decreased by -2.81% in the last trading session.


What is the dividend status of ANI PHARMACEUTICALS INC?

ANIP does not pay a dividend.


How is the ChartMill rating for ANI PHARMACEUTICALS INC?

ANIP has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Where is ANI PHARMACEUTICALS INC (ANIP) stock traded?

ANIP stock is listed on the Nasdaq exchange.


What is ANI PHARMACEUTICALS INC worth?

ANI PHARMACEUTICALS INC (ANIP) has a market capitalization of 1.86B USD. This makes ANIP a Small Cap stock.


Can you provide the ownership details for ANIP stock?

You can find the ownership structure of ANI PHARMACEUTICALS INC (ANIP) on the Ownership tab.